LY2955303 is a selective positive allosteric modulator of the metabotropic glutamate receptor 2 (mGlu2), primarily researched for its potential therapeutic applications in the treatment of neurological and psychiatric disorders. It is being studied for its role in modulating glutamatergic signaling in the brain, which could help in managing conditions like anxiety, depression, schizophrenia, and neurodegenerative diseases. Early-stage research suggests it may have neuroprotective properties, making it a candidate for addressing brain injuries or diseases such as Alzheimer’s. Additionally, its mechanism of action is being explored for its potential to alleviate chronic pain by targeting pain pathways in the central nervous system. Ongoing studies aim to further understand its efficacy and safety in these applications.